Practice parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 69, Issue 1, 2007, Pages 91-102

  Halperin, J J ^a   Shapiro, E D ^b   Logigian, E ^c   Belman, A L ^d   Dotevall, L ^e   Wormser, G P ^f   Krupp, L ^d   Gronseth, G ^g   Bever Jr , C T ^h,i  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h VAMHCS   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; PLACEBO; STEROID;

ANTIBIOTIC THERAPY; BORRELIA INFECTION; BRAIN DISEASE; CLINICAL TRIAL; CRANIAL NEUROPATHY; ENCEPHALOMYELITIS; FACIAL NERVE PARALYSIS; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG EMBOLISM; LYME DISEASE; MENINGITIS; MONONEUROPATHY MULTIPLEX; NERVOUS SYSTEM; NEURITIS; NEUROPATHY; PLEOCYTOSIS; PRIORITY JOURNAL; RADICULOPATHY; REVIEW; TREATMENT DURATION; TREATMENT FAILURE;

EID: 34347395117     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000265517.66976.28     Document Type: Article

References (66)

1. Halperin J, Logigian E, Finkel M, Pearl R. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Neurology 1996;46:619-627.
2. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-1134.
3. Halperin JJ, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis: peripheral nervous system manifestations. Brain 1990;113:1207-1221.
4. Logigian EL, Steere AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992;42:303-311.
5. Klempner M, Hu L, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
6. Krupp L, Hyman L, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003;60:1923-1930.
7. Kaplan R, Trevino R, Johnson G, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003;60:1916-1922.
8. Hellerstrom S. Erythema chronicum migrans Afzelius with meningitis. Acta Derm Venereol 1951;31:227-234.
9. Hollstrom E. Successful treatment of erythema migrans Afzelius. Acta Derm Venereol 1951;31:235-243.
10. Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: successful treatment with highdose intravenous penicillin. Ann Intern Med 1983;99:767-772.
11. Skoldenberg B, Stiernstedt G, Garde A, Kolmodin G, Carlstrom A, Nord C. Chronic meningitis caused by a penicillin-sensitive microorganism. Lancet 1983;II:75-78.
12. Steere AC, Green J, Hutchinson GJ, et al. Treatment of Lyme disease. Zentralbl Bakteriol Mikrobiol Hyg [a] 1987;263:352-356.
13. Dattwyler R, Halperin J, Volkman D, Luft B. Treatment of late Lyme borreliosis-randomised comparison of ceftriaxone and penicillin. Lancet 1988;1:1191-1194.
14. Skoldenberg B, Stiernstedt G, Karlsson M, Wretlind B, Svenungsson B. Treatment of Lyme borreliosis with emphasis on neurological disease. Ann NY Acad Sci 1988;539:317-323.
15. Kohlhepp W, Oschmann P, Mertens H. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. J Neurol 1989;236:464-469.
16. Pfister H, Preac-Mursic V, Wilske B, Einhaupl K. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol 1989;46:1190-1194.
17. Hassler D, Zoller L, Haude M, Hufnagel H, Heinrich F, Sonntag H. Cefotaxime versus penicillin in the late stage of Lyme disease: prospective, randomized therapeutic study. Infection 1990;18:16-20.
18. Pfister H, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl K. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991;163:311-318.
19. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994;44:1203-1207.
20. Borg R, Dotevall L, Hagberg L, et al. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis 2005;37:449-454.
21. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999;28:569-574.
22. Karkkonen K, Stiernstedt S, Karlsson M. Follow-up of patients treated with oral doxycycline for Lyme neuroborreliosis. Scand J Infect Dis 2001;33:259-262.
23. Logigian E, Kaplan R, Steere A. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990;323:1438-1444.
24. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999;180:377-383.
25. Treib J, Fernandez A, Haass A, Grauer M, Holzer G, Woessner R. Clinical and serologic follow-up in patients with neuroborreliosis. Neurology 1998;51:1489-1491.
26. Shadick N, Phillips C, Logigian E, et al. The long-term clinical outcomes of Lyme disease: a population-based retrospective cohort study. Ann Intern Med 1994;121:560-567.
27. Berglund J, Stjernberg L, Ornstein K, Tykesson-Joelsson K, Walter H. 5-y Follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002;34:421-425.
28. Cimperman J, Maraspin V, Lotric-Furlan S, Ruzic-Sabljic E, Strle F. Lyme meningitis: a one-year follow up controlled study. Wiener Klinische Wochenschrift 1999;111:961-963.
29. Seltzer E, Gerber M, Cartter M, Freudigman K, Shapiro E. Long-term outcomes of persons with Lyme disease. JAMA 2000;283:609-616.
30. Oksi J, Nikoskelainen J, Viljanen M. Comparison of oral cefixime and intravenous ceftriaxone followed by oral amoxicillin in disseminated Lyme borreliosis. Eur J Clin Microbiol Infect Dis 1998;17:715-719.
31. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme borreliosis. J Infect 1994;29:255-261.
32. Karlsson M, Hammers S, Nilsson-Ehle I, Malmborg A, Wretlind B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 1996;40:1104-1107.
33. Krbkova L, Stanek G. Therapy of Lyme borreliosis in children. Infection 1996;24:170-173.
34. Kruger H, Kohlhepp W, Konig S. Follow-up of antibiotically treated and untreated neuroborreliosis. Acta Neurol Scand 1990;82:59-67.
35. Thorstrand C, Belfrage E, Bennet R, Malmborg P, Eriksson M. Successful treatment of neuroborreliosis with ten day regimens. Pediatr Infect Dis J 2002;21:142-145.
36. Dotevall L, Borg R, Hagberg L. Doxycycline treatment of Lyme neuroborreliosis with meningoradiculitis and/or myeloencephalopathy. Submitted.
37. Vázquez M, Sparrow S, Shapiro E. Long-term neuropsychologic and health outcomes of children with facial nerve palsy due to Lyme disease. Pediatrics 2003;112:93-97.
38. Baradaran-Dilmaghani R, Stanek G. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 1996;24:60-63.
39. Sicklinger M, Wienecke R, Neubert U. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. J Clin Microbiol 2003;41:1791-1793.
40. Hansen K, Lebech A. The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985-1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 1992;115:399-423.
41. Belman AL, Reynolds L, Preston T, Postels D, Grimson R, Coyle PK. Cerebrospinal fluid findings in children with Lyme disease-associated facial nerve palsy. Arch Pediatr Adolesc Med 1998;152:928-929.
42. Shapiro E, Gerber M. Lyme disease and facial nerve palsy: More questions than answers. Arch Pediatr Adolesc Med 1998;152:1183-1184.
43. Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:830-836.
44. Corticosteroids for Bell's palsy (idiopathic facial paralysis). John Wiley and Sons, 2006. Accessed at: http://www-.cochrane.org/reviews/en/ab001942. html.
45. Bentas W, Karch H, Huppertz H. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol 2000;27:2025-2030.
46. Pachner AR, Amemiya K, Bartlett M, Schaefer H, Reddy K, Zhang WF. Lyme borreliosis in rhesus macaques: effects of corticosteroids on spirochetal load and isotype switching of anti-Borrelia burgdorferi antibody. Clin Diagn Lab Immunol 2001;8:225-232.
47. Pfister HW, Einhaupl KM, Franz P, Garner C. Corticosteroids for radicular pain in Bannwarth's syndrome: a double blind, randomized, placebo controlled trial. Ann NY Acad Sci 1988;539:485-487.
48. Massengo SA, Bonnet F, Braun C, Vital A, Beylot J, Bastard J. Severe neuroborreliosis: the benefit of prolonged high-dose combination of antimicrobial agents with steroids: an illustrative case. Diagn Microbiol Infect Dis 2005;51:127-130.
49. Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope 1985; 95:1341-1345.
50. Kalish R, Kaplan R, Taylor E, Jones-Woodward L, Workman K, Steere A. Evaluation of study patients with Lyme disease, 10-20-year follow-up. J Infect Dis 2001;183:453-460.
51. Belman AL, Iyer M, Coyle PK, Dattwyler R. Neurologic manifestations in children with North American Lyme disease. Neurology 1993;43:2609-2614.
52. Eichenfield A, Goldsmith D, Benach J, et al. Childhood Lyme arthritis: experience in an endemic area. J Pediatr 1986;109:753-758.
53. Salazar J, Gerber M, Goff C. Long-term outcome of Lyme disease in children given early treatment. J Pediatr 1993;122:591-593.
54. Christen H, Hanefeld F, Eiffert H, Thomssen R. Epidemiology and clinical manifestations of Lyme borreliosis in childhood. A prospective multicentre study with special regard to neuroborreliosis. Acta Paediatr Suppl 1993;386:1-75.
55. Millner M, Thalhammer G. Neuroborreliosis in childhood: treatment with penicillin sodium and ceftriaxone. Acta Dermatovenerologica Alpina, Panonica et Adriatica 1996;5:169-172.
56. Mullegger R, Millner M, Stanek G, Spork K. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children-a prospective study. Infection 1991;19:279-283.
57. Gerber M, Shapiro E, Burke G, Parcells V, Bell G. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group.NEngl J Med 1996;335:1270-1274.
58. Jorbeck H, Gustafsson P, Lind H, Stiernstedt G. Tickborne Borrelia-meningitis in children. An outbreak in the Kalmar area during the summer of 1984. Acta Paediatr Scand 1987;76:228-233.
59. Halperin JJ, Luft BJ, Anand AK, et al. Lyme neuroborreliosis: central nervous system manifestations. Neurology 1989;39:753-759.
60. Hunfield K-P, Kraiczy P, Kekoukh E, Schafer V, Brade V. Standardized in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents- Possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol 2002;291(suppl 33):125-137.
61. Hunfield K-P, Ruzic-Sabljic E, Norris D, Kraiczy P, Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 2005;49:1294-1301.
62. Nowakowski J, Wormser G. Treatment of early Lyme disease: infection associated with erythema migrans. In: Coyle P, ed. Lyme disease. St. Louis, MO: Mosby-Year Book; 1993:149-162.
63. Nowakowski J, Nadelman R, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003;115:91-96.
64. Wormser G. Lyme disease. Insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections. Mt Sinai J Med 1995;62:188-195.
65. Asch E, Bujak D, Weiss M, Peterson M, Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 1994;21:454-461.
66. th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases; September 11-15; 2005; Vienna, Austria; 2005:196.